BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

23 related articles for article (PubMed ID: 22082104)

  • 1. Nutlin-3 Loaded Ethosomes and Transethosomes to Prevent UV-Associated Skin Damage.
    Esposito E; Ferrara F; Drechsler M; Bortolini O; Ragno D; Toldo S; Bondi A; Pecorelli A; Voltan R; Secchiero P; Zauli G; Valacchi G
    Life (Basel); 2024 Jan; 14(1):. PubMed ID: 38276284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic.
    Wang Q; Shen X; Chen G; Du J
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TRIM Proteins in Colorectal Cancer: TRIM8 as a Promising Therapeutic Target in Chemo Resistance.
    Marzano F; Caratozzolo MF; Pesole G; Sbisà E; Tullo A
    Biomedicines; 2021 Feb; 9(3):. PubMed ID: 33673719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas.
    Crane EK; Kwan SY; Izaguirre DI; Tsang YT; Mullany LK; Zu Z; Richards JS; Gershenson DM; Wong KK
    PLoS One; 2015; 10(8):e0135101. PubMed ID: 26248031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P53 mutations in colorectal cancer - molecular pathogenesis and pharmacological reactivation.
    Li XL; Zhou J; Chen ZR; Chng WJ
    World J Gastroenterol; 2015 Jan; 21(1):84-93. PubMed ID: 25574081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting p53-MDM2-MDMX loop for cancer therapy.
    Zhang Q; Zeng SX; Lu H
    Subcell Biochem; 2014; 85():281-319. PubMed ID: 25201201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging anti-proliferative role of Nutlin-3 in the pathogenesis of systemic malignancies.
    Kapoor S
    Cancer Biol Ther; 2013 Jan; 14(1):5. PubMed ID: 23114642
    [No Abstract]   [Full Text] [Related]  

  • 8. Nanoparticles loaded with Nutlin-3 display cytotoxicity towards p53(wild-type) JVM-2 but not towards p53(mutated) BJAB leukemic cells.
    Voltan R; Secchiero P; Ruozi B; Caruso L; Forni F; Palomba M; Zauli G; Vandelli MA
    Curr Med Chem; 2013; 20(21):2712-22. PubMed ID: 23627936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer.
    Nadler-Milbauer M; Apter L; Haupt Y; Haupt S; Barenholz Y; Minko T; Rubinstein A
    J Drug Target; 2011 Dec; 19(10):859-73. PubMed ID: 22082104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cepharanthine exhibits a potent anticancer activity in p53-mutated colorectal cancer cells through upregulation of p21Waf1/Cip1.
    Rattanawong A; Payon V; Limpanasittikul W; Boonkrai C; Mutirangura A; Wonganan P
    Oncol Rep; 2018 Jan; 39(1):227-238. PubMed ID: 29138869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression.
    Palani CD; Beck JF; Sonnemann J
    Invest New Drugs; 2012 Feb; 30(1):25-36. PubMed ID: 20680659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.